Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | CRHBP | P24387 | 1/20 | 0.56 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13251238 | 0.92 | MAPT (0.58) | MAPTGAACRHBPCRHR2L3MBTL1 | |
| SCHEMBL8117366 | 0.89 | MAPT (0.65) | TDP1MAPTGAACRHBPCRHR2 | |
| SCHEMBL6138558 | 0.87 | MAPT (0.57) | MAPTGAACRHBPCRHR2L3MBTL1 | |
| SCHEMBL21104434 | 0.87 | MAPT (0.53) | MAPTGAACRHBPCRHR2L3MBTL1 | |
| SCHEMBL21104158 | 0.87 | MAPT (0.53) | MAPTGAACRHBPCRHR2L3MBTL1 | |
| SCHEMBL5141282 | 0.83 | MAPT (0.53) | MAPTGAACRHBPCRHR2L3MBTL1 | |
| SCHEMBL6228523 | 0.83 | MAPT (0.65) | MAPTGAAL3MBTL1KCNH2ALDH1A1 | |
| SCHEMBL27882210 | 0.83 | MAPT (0.56) | TDP1MAPTCRHBPCRHR2L3MBTL1 | |
| SCHEMBL3045885 | 0.82 | MAPT (0.68) | MAPTGAACRHBPCRHR2KCNH2 | |
| SCHEMBL9482551 | 0.82 | MAPT (0.59) | TDP1MAPTGAACRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382218-A1 | DELTA-5-DESATURASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010087467-A1 | DELTA-5-DESATURASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | WO | disclosed |
| US-20100190747-A1 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20080227858-A1 | Inhibitors of matrix metalloproteinase | GLAXO GROUP LIMITED | 2008-09-18 | — | — | US | disclosed |
| US-20080227858-A1 | Inhibitors of matrix metalloproteinase | GLAXO GROUP LIMITED | 2008-09-18 | — | — | US | disclosed |
| US-7375248-B2 | Inhibitors of matrix metalloproteinase | GLAXO GROUP LIMITED (GB) | 2008-05-20 | — | — | US | disclosed |
| US-7375248-B2 | Inhibitors of matrix metalloproteinase | GLAXO GROUP LIMITED (GB) | 2008-05-20 | — | — | US | disclosed |
| US-20060142385-A1 | Inhibitors of matrix metalloproteinase | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
| EP-1636174-A1 | INHIBITORS OF MATRIX METALLOPROTEINASE | GLAXO GROUP LIMITED (GB) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004113279-A1 | INHIBITORS OF MATRIX METALLOPROTEINASE | GLAXO GROUP LIMITED (GB) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004113279-A1 | INHIBITORS OF MATRIX METALLOPROTEINASE | GLAXO GROUP LIMITED (GB) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142385-A1 | Inhibitors of matrix metalloproteinase | MMP9, MMP13, MMP26 | TDP1 4680/4885MAPT 4758/4885GAA 1204/4885 |
| US-20100190747-A1 | Fused ring compound and use thereof | CYP46A1, LTB4R2, PTGES | TDP1 3961/4885MAPT 2366/4885GAA 3631/4885 |
| US-20080227858-A1 | Inhibitors of matrix metalloproteinase | MMP9, MMP13, MMP2 | TDP1 4650/4885MAPT 4758/4885GAA 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.